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CASE LETTERSFig 1. Rosacea, patient 1. Four hours after application of
brimonidine tartrate to cheeks and nose. Note that ery-
thema is absent from her forehead, where the medication
was not applied.Rebound erythema and burning sensation
from a new topical brimonidine tartrate gel
0.33%
To the Editor: Brimonidine tartrate (BT) gel 0.33%
(Mirvaso, Galderma Laboratories LP), an alpha-2
selective adrenergic receptor agonist and vasocon-
strictor, reduces erythema of rosacea.1-3 The top 3
reported adverse events related to BT are erythema
worse than baseline (4%), flushing (3%), and
burning (2%). At least 1% of patients had an adverse
reaction to the medication.1,3
We report severe erythema in conjunction with
burning sensation in 3 patients using BT. All reported
reduced erythema 1 to 6 hours after application,
followed by self-limited erythema, more severe
than baseline, accompanied by burning over the next
12 hours and lasting roughly 12 hours. This phenom-
enon worsens with continued use. Urticaria and facial
edemawere absent. Even though theMirvaso package
insert reports infrequent erythema worse than base-
line, this number may be higher in practice.1,2
Patient 1. A 36-year-old Latina woman with long-
standing rosacea and Hashimoto thyroiditis applied
BT to cheeks and nose as directed. Erythema reduc-
tion lasting 4hourswas followedbyerythema, notably
elevatedoverbaseline, andburning in the areaswhere
theBTwas applied (Fig 1). This reaction resolved after
5 hours. The patient continued to use the BT over the
courseof 5 days, applying in 5 areas, as directed, to her
forehead, each cheek, nose, and chin. She felt the
reduction in erythema was satisfactory but noted that
patchy erythema and burning developed 5 to 10 hours
after application. On the 5th day of use, 12 hours after
application, she experienced erythema, much worse
than at baseline, in all areas where themedication had
been applied and she had a severe skin burning
sensation (Fig 2). The erythema and burning resolved
12 hours later and she discontinued use of BT.
Patient 2. A 41-year-old Caucasian woman with
long-standing rosacea, psoriasis, and anxiety re-
ported reduced erythema following one application
of BT, followed 3 hours later by significant erythema,
skin burning, and pruritus where BT was applied.
These resolved slowly over the next 12 hours.
Concurrent medications included infliximab, meth-
otrexate, folic acid, venlafaxine, zolpidem, clonaze-
pam, and trazodone.
Patient 3. A 28-year-old Caucasian woman with
long-standing rosacea and Hashimoto thyroiditis,J AM ACAD DERMATOL
Open access under CC BY-NC-ND license.taking levothyroxine, tramadol, and norethindrone/
ethinyl estradiol, applied BT to cheeks and chin once
daily for 2 weeks. She noted significant reduction in
erythema followed 6 to 8 hours later by erythema and
burning in the areas of application. She continued
therapy for 2 weeks with progressively worsening
rebound erythema and burning. These symptoms
resolved temporarily with reapplication of BT.
There is no current photo documentation of
this side effect at www.mirvaso.com or in the litera-
ture.3 We propose that this reaction constitutes
rebound dilation of the capillaries caused by
down-regulation of alpha-2 adrenergic receptors
following use of BT. This may be similar to
rhinitis medicamentosa, observed with overuse ofFEBRUARY 2014 e37
Fig 2. Rosacea, patient 1. Twelve hours after application
of brimonidine tartrate to forehead, cheeks, nose, and
chin. Erythema is present in all of the areas where the
medication was applied.
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line and xylometazoline).4 This reaction directly
opposes the goal of therapy.
Counseling about the potential for worsening
erythema, use of a test area, and limiting use to
special occasions may bewarranted. Viewing images
of this adverse reaction prior to use may alleviate
patient distress.
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cyclosporine and isotretinoin
To the Editor: Acne fulminans (AF) is a rare and very
severe form of acne characterized by the sudden
onset of painful, ulcerative pustules and associated
systemic symptoms. Recommended treatment is a
combination of oral steroids and isotretinoin. We
report the case of a male patient with poor response
to this treatment who was successfully treated with
the combination of oral cyclosporine and
isotretinoin.
A 15-year-old white male patient with severe acne
flare was referred to our hospital. Diagnosis was
acne vulgaris for the past 2 years, treated with topical
antibiotics. Six months before the consultation, the
lesions worsened and a diagnosis of acne conglobata
was made. He was treated with isotretinoin 20 mg/
day and prednisone 15 mg/day, but there was no
clinical improvement. Isotretinoin dosage was
increased to 30 mg/day, but 3 weeks later multiple
reddish papulonodular and ulcerated lesions with
hemorrhagic crusts suddenly developed on his face,
neck, and trunk. The lesions were painful, and
arthralgias and temperature up to 398C were noted
(Fig 1). Abnormal laboratory findings included
elevated C-reactive protein levels (5 mg/dL; normal
\ 1 mg/dL) and leukocytosis (15,700 cells/mm3)
with neutrophilia (68.8%). AF was diagnosed, and
treatment with prednisone 60 mg/day and isotreti-
noin 20mg/day was initially successful. Nevertheless
progressive worsening was observed in the
following weeks while prednisone was tapered
and isotretinoin increased to 30 mg/day. He was
treated with potassium permanganate baths and
topical antibiotics. Oral cyclosporine 5 mg/kg/day
plus isotretinoin 30 mg/day was initiated and
systemic steroids were stopped. After a few weeks,
